These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36039519)

  • 21. GLP1 Receptor Agonist and SGLT2 Inhibitor Combination: An Effective Approach in Real-world Clinical Practice.
    Díaz-Trastoy O; Villar-Taibo R; Sifontes-Dubón M; Mozo-Peñalver H; Bernabeu-Morón I; Cabezas-Agrícola JM; Muñoz-Leira V; Peinó-García R; Martís-Sueiro A; García-López JM; Martínez-Olmos MA
    Clin Ther; 2020 Feb; 42(2):e1-e12. PubMed ID: 32005534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation.
    Ertuglu LA; Porrini E; Hornum M; Demiray A; Afsar B; Ortiz A; Covic A; Rossing P; Kanbay M
    Transpl Int; 2021 Aug; 34(8):1341-1359. PubMed ID: 33880815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD.
    Farmer RE; Beard I; Raza SI; Gollop ND; Patel N; Tebboth A; McGovern AP; Kanumilli N; Ternouth A
    Clin Ther; 2021 Feb; 43(2):320-335. PubMed ID: 33581878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice.
    Fu EL; Clase CM; Janse RJ; Lindholm B; Dekker FW; Jardine MJ; Carrero JJ
    Int J Cardiol; 2022 Apr; 352():172-179. PubMed ID: 35074492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
    Gallwitz B; Dagogo-Jack S; Thieu V; Garcia-Perez LE; Pavo I; Yu M; Robertson KE; Zhang N; Giorgino F
    Diabetes Obes Metab; 2018 Feb; 20(2):409-418. PubMed ID: 28817231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
    Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
    Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis.
    Driessen JH; Henry RM; van Onzenoort HA; Lalmohamed A; Burden AM; Prieto-Alhambra D; Neef C; Leufkens HG; de Vries F
    Calcif Tissue Int; 2015 Aug; 97(2):104-12. PubMed ID: 25894068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D).
    Ghosal S; Datta D; Sinha B
    Sci Rep; 2021 Nov; 11(1):22063. PubMed ID: 34764398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?
    Updike WH; Pane O; Franks R; Saber F; Abdeen F; Balazy DD; Carris NW
    Drugs; 2021 Jun; 81(8):881-893. PubMed ID: 33929717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes.
    Xu Y; Fu EL; Clase CM; Mazhar F; Jardine MJ; Carrero JJ
    Kidney Int; 2022 Feb; 101(2):360-368. PubMed ID: 34826514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.
    Terauchi Y; Usami M; Inoue T
    Adv Ther; 2022 Jun; 39(6):2873-2888. PubMed ID: 35449321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors and Clinical Outcomes of Treatment Intensification in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting.
    Kallenbach L; Shui AM; Cheng WY; Fan T; Hu W; Zichlin ML; Duh MS; Ye F; Levin PA
    Endocr Pract; 2018 Sep; 24(9):805-814. PubMed ID: 29975575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data.
    Trautmann ME; Han J; Ruggles J
    Clin Ther; 2016 Jun; 38(6):1464-1473. PubMed ID: 27126504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Intensive Insulin Versus Oral Regimens on Early Glycemic Control Following Kidney Transplant.
    Petrosan A; Santeusanio AD; Khaim R; Delaney V
    Prog Transplant; 2022 Dec; 32(4):327-331. PubMed ID: 36114645
    [No Abstract]   [Full Text] [Related]  

  • 35. Improved Clinical Outcomes with Dulaglutide as Add-on Medication to Oral Antidiabetic Drugs with or Without Insulin in Overweight Indian Patients with Type 2 Diabetes Mellitus: Retrospective Study in a Real-World Setting.
    Ghosh A; Nair R
    Curr Diabetes Rev; 2020; 16(5):490-496. PubMed ID: 31686642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review.
    González-González JG; Díaz González-Colmenero A; Millán-Alanís JM; Lytvyn L; Solis RC; Mustafa RA; Palmer SC; Li S; Hao Q; Alvarez-Villalobos NA; Vandvik PO; Rodríguez-Gutiérrez R
    BMJ Open; 2021 Jul; 11(7):e049130. PubMed ID: 34244276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Investigation on the Efficacy of Glucagon-Like Peptide 1 Receptor Agonists Drugs in Reducing Urine Albumin-to-Creatinine Ratio in Patients With Type 2 Diabetes: A Potential Treatment for Diabetic Nephropathy.
    Yarlagadda C; Abutineh M; Reddy AJ; Landau AB; Travis LM; Perrone CG; Idriss A; Patel R
    Cureus; 2023 Mar; 15(3):e36438. PubMed ID: 37090383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycemic management and clinical outcomes in underserved minority kidney transplant recipients with type 2 and posttransplantation diabetes: A single-center retrospective study.
    Aleksic S; Eisenberg R; Tsomos E; Zahedpour Anaraki S; Japp E; Upadhyay L; Mowrey WB; Akalin E; Zonszein J
    Diabetes Res Clin Pract; 2020 Jul; 165():108221. PubMed ID: 32442553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes.
    Varshney N; Billups SJ; Saseen JJ; Fixen CW
    Ther Adv Drug Saf; 2021; 12():2042098621997703. PubMed ID: 33854754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Retrospective Study of Glucagon-Like Peptide 1 Receptor Agonists for the Management of Diabetes After Transplantation.
    Thangavelu T; Lyden E; Shivaswamy V
    Diabetes Ther; 2020 Apr; 11(4):987-994. PubMed ID: 32072430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.